

# HERITABLE INFLUENCES IN EXPERIMENTAL RETINOPATHY OF PREMATURITY

---

Melinda Tea

Bachelor of Laboratory Medicine (Hons)

Thesis submitted for the degree of

Doctor of Philosophy

February 2012

Faculty of Health Sciences

School of Medicine

Department of Ophthalmology

Flinders University of South Australia

Adelaide, Australia

## TABLE OF CONTENTS

<b>HERITABLE INFLUENCES IN EXPERIMENTAL RETINOPATHY OF PREMATURITY .....</b>	<b>i</b>
TABLE OF CONTENTS .....	ii
SUMMARY OF THESIS .....	xiv
PUBLICATIONS ARISING FROM THIS THESIS.....	xvii
PRESENTATIONS ARISING FROM THIS THESIS.....	xvii
DECLARATION.....	xix
ACKNOWLEDGEMENTS.....	xx
ABBREVIATIONS.....	xxiii
<b>CHAPTER 1: INTRODUCTION.....</b>	<b>1</b>
1.1. OVERVIEW .....	2
1.2 RETINAL ANATOMY.....	2
1.3 BLOOD SUPPLY TO THE RETINA .....	4
1.4 RETINAL VASCULAR DEVELOPMENT .....	4
1.4.a Growth factors involved in retinal vascular development.....	5
1.4.a.1 Vascular endothelial growth factor .....	8
1.4.b Hypoxia-inducible factor-1 $\alpha$ .....	8
1.4.b.1 HIF-1 $\alpha$ and HIF-2 $\alpha$ in the retina .....	9
1.4.b.2 HIF- $\alpha$ degradation in normoxia.....	10
1.4.b.3 Transcriptional activity of HIF in hypoxia .....	10
1.5 RETINOPATHY OF PREMATURITY.....	12

1.5.a	Clinical and genetic risk factors of ROP.....	14
1.5.b	Oxygen-induced retinopathy as an animal model of ROP.....	17
1.5.b.1	Strain-related differences in susceptibility to OIR in the rat ... .....	18
1.6	MICRORNAs .....	19
1.6.a	Discovery of microRNAs.....	19
1.6.b	Biogenesis of microRNAs .....	20
1.6.c	Formation of the RISC and mechanism of microRNA action .....	22
1.6.d	MicroRNA expression in the eye.....	23
1.6.e	MicroRNAs and hypoxia.....	26
1.6.f	MicroRNA and angiogenesis .....	27
1.6.f.1	Pro-angiogenic miRNAs .....	28
1.6.f.2	Anti-angiogenic miRNAs.....	28
1.6.g	Role of microRNAs in a mouse model of oxygen-induced retinopathy .....	29
1.6.h	MicroRNAs as therapeutic drugs.....	29
1.7	ROP: WHAT WE KNOW AND WHERE TO NOW.....	32
1.8.	HYPOTHESIS AND AIMS.....	33
<b>CHAPTER 2: MATERIALS AND METHODS.....</b>		<b>34</b>
2.1	MATERIALS.....	35
2.1.a	Water.....	35
2.1.b	General chemicals .....	35
2.1.c	Enzymes .....	35
2.1.d	PCR primers.....	36

2.1.e	Experimental animals.....	41
2.1.e.1	Ethical treatment of animals.....	41
2.1.e.2	Rats.....	41
2.1.f	Miscellaneous materials.....	42
2.2	BUFFERS AND SOLUTIONS.....	43
2.2.a	DEPC-NaCl.....	43
2.2.b	Chrome alum-subbed microscope slides .....	43
2.2.c	Phosphate Buffered Saline (PBS 10 x) .....	43
2.2.d	Sodium Hydroxide stock 10M .....	44
2.2.e	Phosphate buffers 0.2M (pH 7.4) .....	44
2.2.f	Paraformaldehyde (4%) in 0.1M phosphate buffer.....	44
2.2.g	Electrophoresis gel DNA/RNA loading buffer .....	45
2.2.h	EDTA Buffer (0.5 x) .....	45
2.2.i	Tris Borate EDTA buffer (TBE 10 x).....	45
2.3	ANIMAL AND TISSUE TECHNIQUES .....	46
2.3.a	Oxygen-induced retinopathy .....	46
2.3.a.1	Oxygen chamber .....	46
2.3.a.2	Exposure of neonatal rats to cyclic hyperoxia .....	48
2.3.b	Retinal dissection and histochemistry .....	50
2.3.c	Image analysis of isolectin-labelled retinae .....	52
2.3.c.1	Avascular area analysis of isolectin-labelled retinae .....	53
2.3.c.2	Retinal vessel tortuosity analysis of isolectin-labelled retinae .....	54
2.4	MOLECULAR TECHNIQUES .....	55
2.4.a	RNA collection time line.....	55

2.4.b	Collection of rat retinae for microarray analysis.....	56
2.4.c	Collection of rat retinae for real-time RT-PCR analysis.....	58
2.4.d	Total RNA extraction from rat retinae.....	59
2.4.e	Quantification and determination of RNA integrity.....	61
2.4.f	Preparation of test RNA samples for mRNA microarray analysis.....	62
2.4.g	Affymetrix mRNA microarrays.....	64
2.4.h	DNase treatment of RNA extracts.....	66
2.4.i	Preparation of the standard mRNA sample.....	67
2.4.j	cDNA synthesis of the standard mRNA sample.....	68
2.4.k	cDNA synthesis of test samples.....	69
2.4.l	PCR primer design for gene expression.....	70
2.4.m	Agarose gel electrophoresis.....	72
2.4.n	Agarose gel PCR product purification.....	72
2.4.o	PCR product sequencing.....	73
2.4.p	General precautions for PCR.....	73
2.4.q	Quantitative real-time RT-PCR for gene expression.....	73
2.4.r	Relative quantification of retinal gene expression.....	75
2.4.s	Exiqon microRNA microarrays.....	75
2.4.t	Preparation of the standard microRNA sample.....	79
2.4.u	Quantitative real-time RT-PCR for microRNA expression.....	79
2.4.v	Determination of primer amplification efficiencies and optimal template concentration for quantitative real-time RT-PCR.....	82
2.4.w	Selection and validation of a small RNA reference gene.....	82
2.4.x	Relative quantification and normalisation of retinal microRNA expression.....	84

2.4.y	microRNA databases and microRNA target prediction programs.....	86
2.5	STATISTICAL ANALYSIS.....	87
2.5.a	Retinal avascular area and vascular morphology.....	87
2.5.b	Affymetrix gene expression microarrays.....	88
2.5.c	Exiqon microRNA microarrays.....	88
2.5.d	Real-time PCR data.....	89
<b>CHAPTER 3: RESULTS - INHERITANCE OF STRAIN-DEPENDENT DIFFERENCES IN EXPERIMENTAL RETINOPATHY OF PREMATURITY.....</b>		<b>90</b>
3.1	ABSTRACT.....	91
3.1a	Introduction.....	91
3.2	RESULTS.....	94
3.2.a	Strain comparisons of retinal vascularisation in response to cyclic hyperoxia.....	94
3.2.a.1	Retinal vascularisation in F344 x SD rats in response to cyclic hyperoxia.....	96
3.2.b	Criteria for determining susceptibility to OIR.....	97
3.2.b.1	Retinal avascular area.....	97
3.2.b.2	Retinal blood vessel tortuosity.....	101
3.2.b.3	Determining susceptibility to OIR in cyclic hyperoxia-exposed F344 and SD rats.....	102
3.2.c	Cross-breeding experiments.....	103
3.2.c.1	Susceptibility of F344 x SD offspring to OIR.....	104
3.2.c.2	Susceptibility of backcross offspring to OIR.....	105

3.2.c.2.a	Susceptibility of F1 x F344 backcross offspring to OIR.....	106
3.2.c.2.b	Susceptibility of F1 x SD backcross offspring to OIR..	107
3.2.c.3	Genetic modelling of susceptibility to OIR .....	109
3.3	DISCUSSION .....	111
3.3.a	Summary of findings.....	111
3.3.b	Ocular pigmentation and susceptibility to OIR .....	112
3.3.c	Genetic modifiers in disease.....	114
3.3.d	Genetic modifiers in ROP and OIR .....	115
3.3.e	CONCLUSION.....	120
<b>CHAPTER 4: RESULTS - ALTERED GENE EXPRESSION IN OXYGEN-INDUCED RETINOPATHY.....</b>		<b>121</b>
4.1	ABSTRACT.....	122
4.1a	Introduction.....	122
4.1.a.1	HIF- $\alpha$ and the response to hypoxia .....	123
4.1.a.2	Specific aims and overview of approach.....	125
4.2	AFFYMETRIX MICROARRAY RESULTS.....	126
4.2.a	Statistical analysis of microarray data .....	128
4.2.a.1	Principal Components Analysis of microarray data.....	129
4.2.a.2	Number of genes which reached statistical significance....	133
4.2.b	Identification of candidate genes involved in susceptibility to OIR .....	136
4.2.b.1	Identification of candidate genes at day 3.....	137
4.2.b.1.a	Fold change analysis of differentially regulated genes at day 3 .....	140

4.2.b.2	Identification of candidate genes at days 5 and 6 .....	146
4.2.b.2.a	Identification of candidate genes at day 5.....	146
4.2.b.2.b	Identification of candidate genes at day 6.....	150
4.2.c	Selection of gene candidates for validation at days 3, 5 and 6.... .....	156
4.2.c.1.a	Prolyl hydroxylases EGLN3 and EGLN1.....	157
4.2.c.1.b	Monocarboxylate transporter SLC16A3.....	158
4.2.c.1.c	BCL2/adenovirus interacting protein BNIP3.....	159
4.2.c.1.d	Glucose phosphorylation enzyme HK2.....	159
4.2.c.1.e	Insulin-like growth factor binding proteins IGFBP2 and IGFBP3 .....	159
4.3	STRAIN DIFFERENCES IN RETINAL GENE EXPRESSION FOLLOWING EXPOSURE TO CYCLIC HYPEROXIA .....	160
4.3.a	Confirmation of PCR primer specificity and determination of primer PCR amplification efficiencies.....	161
4.3.a.1	Confirmation of PCR primer specificity.....	161
4.3.a.2	Determination of primer PCR amplification efficiencies.....	165
4.3.b	Confirmation of gene expression in pooled RNA.....	168
4.3.b.1	EGLN3 mRNA expression at day 3 in pooled RNA.....	168
4.3.b.2	EGLN1 mRNA expression at day 3 in pooled RNA.....	170
4.3.b.3	SLC16A3 mRNA expression at day 3 in pooled RNA.....	172
4.3.b.4	HK2 mRNA expression at day 3 in pooled RNA.....	173
4.3.b.5	BNIP3 mRNA expression at day 3 in pooled RNA.....	175
4.3.b.6	IGFBP2 mRNA expression at day 3 in pooled RNA.....	176
4.3.b.7	IGFBP3 mRNA expression at day 3 in pooled RNA.....	178
4.3.c	Confirmation of gene expression in individual rats.....	179



4.3.c.1	EGLN3 mRNA expression.....	180
4.3.c.1.a	EGLN3 mRNA expression at day 3 .....	180
4.3.c.1.b	EGLN3 mRNA expression at day 5 .....	181
4.3.c.1.c	EGLN3 mRNA expression at day 6.....	182
4.3.c.2	EGLN1 mRNA expression.....	183
4.3.c.2.a	EGLN1 mRNA expression at day 3 .....	183
4.3.c.2.b	EGLN1 mRNA expression at day 5 .....	184
4.3.c.2.c	EGLN1 mRNA expression at day 6.....	185
4.3.c.3	IGFBP3 mRNA expression.....	186
4.3.c.3.a	IGFBP3 mRNA expression at day 3 .....	186
4.3.c.3.b	IGFBP3 mRNA expression at day 5.....	187
4.3.c.3.c	IGFBP3 mRNA expression at day 6 .....	188
4.3.d	Summary of EGLN3, EGLN1 and IGFBP3 expression in individual rats at days 3, 5 and 6 .....	189
4.3.d.1	Summary of EGLN3 expression at days 3, 5, and 6 .....	189
4.3.d.2	Summary of EGLN1 expression at days 3, 5, and 6 .....	191
4.3.d.3	Summary of IGFBP3 expression at days 3, 5, and 6.....	193
4.4	DISCUSSION .....	195
4.4.a	Summary of findings.....	195
4.4.b.	Microarray analysis of differential gene expression in the early stages of OIR .....	197
4.4.c	Biological interpretation of strain-dependent differences in gene expression in response to cyclic hyperoxia and susceptibility to OIR .....	199
4.4.c.1	Expression of SLC16A3, HK2 and BNIP3 in response to cyclic hyperoxia.....	199

4.4.c.2	Strain-dependent differential expression of EGLN3 and EGLN1 in response to cyclic hyperoxia and the HIF- $\alpha$ oxygen sensing pathway .....	200
4.4.c.3	Strain-dependent differential expression of IGFBP3 in response to cyclic hyperoxia .....	204
4.4.d	CONCLUSION.....	206
<b>CHAPTER 5: RESULTS - ALTERED miRNA EXPRESSION IN OXYGEN-INDUCED RETINOPATHY.....</b>		<b>208</b>
5.1	ABSTRACT.....	209
5.1a	Introduction.....	210
5.1.b	Specific aims .....	212
5.2	EXIQON MICROARRAY RESULTS.....	212
5.2.a	Analysis of microarray data .....	213
5.2.b	Identification of candidate microRNAs.....	215
5.2.b.1	Identification of microRNA candidates at day 3.....	218
5.2.b.2	Identification of microRNA candidates at day 5.....	221
5.2.b.3	Identification of microRNA candidates at day 6.....	224
5.2.b.4	Summary of microRNA candidates chosen for confirmation by quantitative real-time RT-PCR .....	226
5.3.	SELECTION AND VALIDATION OF SMALL RNA REFERENCE GENES FOR NORMALISATION OF MICRORNA EXPRESSION .....	230
5.4.	INVESTIGATION OF MICRORNA EXPRESSION IN INDIVIDUAL RATS .....	234
5.5	SUMMARY OF MICRORNA EXPRESSION IN INDIVIDUAL RATS FOLLOWING EXPOSURE TO CYCLIC HYPEROXIA.....	236

5.5.a.	miR-30e expression in individual rats at days 3, 5, and 6.....	236
5.5.b	miR-338 expression in individual rats at days 3, 5, and 6.....	238
5.5.c	miR-210 expression in individual rats at days 3, 5, and 6.....	240
5.6	DISCUSSION .....	242
5.6.a	Summary of findings.....	242
5.6.b.	Microarray analysis of differential microRNA expression in the early stages of OIR.....	244
5.6.c	Biological interpretation of strain-related differences in microRNA expression in response to cyclic hyperoxia and susceptibility to OIR.....	245
5.6.c.1	Strain-dependent differential expression of miR-30e and the HIF- $\alpha$ oxygen sensing pathway.....	247
5.6.c.2	Strain-dependent differential expression of miR-338 and the HIF- $\alpha$ oxygen sensing pathway.....	248
5.6.c.3	Strain-dependent differential expression of miR-210 and the HIF- $\alpha$ oxygen sensing pathway.....	249
5.6.c.4	Summary of strain-dependent differential microRNA expression in susceptibility to OIR.....	250
5.6.d	CONCLUSION.....	252
<b>CHAPTER 6: DISCUSSION .....</b>		<b>253</b>
6.1	OVERVIEW .....	254
6.2	FINDINGS FROM THESE STUDIES.....	254
6.2.a	Inheritance of susceptibility to OIR in albino F344 and SD rats . .....	254

6.2.b	Changes in retinal gene expression and susceptibility to OIR....	255
6.2.b.1	Prolyl hydroxylase expression and susceptibility to OIR..	255
6.2.b.2	Insulin-like growth factor binding protein 3 expression and susceptibility to OIR.....	258
6.2.c	Changes in retinal microRNA expression and susceptibility to OIR .....	258
6.2.c.1	Biological interpretation of strain-dependent changes in miR-30e expression and the HIF- $\alpha$ oxygen sensing pathway.....	259
6.2.c.2	Biological interpretation of strain-dependent changes in miR-338 expression and the HIF- $\alpha$ oxygen sensing pathway.....	261
6.2.c.3	Biological interpretation of strain-dependent changes in miR-210 expression and the HIF- $\alpha$ oxygen sensing pathway.....	263
6.2.d	Synthesis: strain-dependent changes in gene and microRNA expression in susceptibility to OIR .....	266
6.2.e	A note on the bioinformatics approach.....	269
6.3	AN OVERVIEW OF RELATED STUDIES.....	271
6.3.a	Role of genetic modifiers in inheritance of susceptibility to OIR .....	271
6.3.b	Role of prolyl hydroxylases in susceptibility to OIR.....	273
6.3.c	Role of IGFBP3 in susceptibility to OIR.....	278
6.3.d	Role of microRNAs in susceptibility to OIR.....	280
6.3.e	Temporal gene and microRNA expression in differential susceptibility to OIR.....	281
6.4	CONCLUDING REMARKS .....	287

<b>APPENDIX 1: - Quantitative real-time RT-PCR microRNA expression data in individual rats.....</b>	<b>288</b>
A1.    Candidate microRNA expression in individual rats.....	289
A1.1    miR-30e expression.....	290
A1.1.a    miR-30e expression at day 3 .....	290
A1.1.b    miR-30e expression at day 5.....	291
A1.1.c    miR-30e expression at day 6.....	293
A1.2    miR-338 expression.....	294
A1.2.a    miR-338 expression at day 3 .....	294
A1.2.b    miR-338 expression at day 5.....	296
A1.2.c    miR-338 expression at day 6 .....	297
A1.3    miR-210 expression.....	299
A1.3.a    miR-210 expression at day 3 .....	299
A1.3.b    miR-210 expression at day 5.....	300
A1.3.c    miR-210 expression at day 6 .....	302
BIBLIOGRAPHY .....	304

## **SUMMARY OF THESIS**

Retinopathy of prematurity (ROP) is a potentially blinding eye condition of premature infants exposed to oxygen therapy. Different inbred rat strains exhibit differential susceptibility to oxygen-induced retinopathy (OIR), a robust animal model of ROP which mimics the pathophysiology seen in human disease. Susceptibility to OIR has previously been shown to segregate with ocular pigmentation, and is inherited in an autosomal dominant fashion in pigmented rat strains. The mode in which susceptibility to OIR is inherited in albino rat strains has not previously been determined. Using genetic cross, and backcross analysis, it was determined that susceptibility to OIR is inherited in the same autosomal dominant manner in albino rats, making it likely that genetic modifiers other than ocular pigmentation contribute to disease susceptibility. These modifiers could potentially be involved in the oxygen sensing pathway, which is central to the development of OIR and ROP.

Differences in retinal gene expression are likely to underlie the differential susceptibility to OIR that is exhibited by the two inbred strains of albino rats used in this study. MicroRNAs (miRNAs) may also contribute to the OIR phenotype by regulating these changes in gene expression. To test this hypothesis, RNAs from the retinae of two different rat strains exposed to oxygen therapy for 3, 5 or 6 days were analysed for gene and miRNA

expression using Affymetrix and Exiqon microarrays, respectively. A bioinformatics approach using the freely available online database, Database for Annotation, Visualisation and Integrated Discovery (DAVID), was used to assist in functional grouping of differentially regulated genes, many of which were found to be associated with response to hypoxia.

Candidate genes were identified from the gene expression microarray data based on their regulation by oxygen and on a search of the literature. The gene candidates EGL nine homolog 3 (EGLN3) and EGL nine homolog 1 (EGLN1) belong to a class of oxygen-dependent prolyl hydroxylases which are responsible for regulating levels of hypoxia-inducible factor- $\alpha$  (HIF- $\alpha$ ) in normoxia. HIF- $\alpha$  is a master transcription factor which upregulates the expression of target genes in response to hypoxia. An additional candidate, insulin-like growth factor binding protein 3 (IGFBP3) was also chosen based on evidence from the literature showing that early expression of IGFBP3 was protective against the disease in a mouse model of OIR. Expression of candidate genes was confirmed using relative quantification real-time RT-PCR analysis.

miRNAs are non-coding RNAs which regulate gene expression at a post-transcriptional level and have been associated with a wide variety of physiological and pathological conditions including retinal development and OIR.

Initial analysis of microarray data from all 3 time points showed a total of 15 miRNAs to be differentially expressed after correction for multiple comparisons. miRNAs were identified as candidates if they targeted oxygen-related genes, were regulated by both oxygen and strain or had significant adjusted p values ( $p < 0.05$ ). miRNAs which are differentially regulated by exposure to oxygen therapy in a strain-dependent manner may contribute to differences in the disease phenotype that is exhibited by these two albino rat strains. Three miRNAs of interest, miR-30e, miR-338-3p and miR-210, were chosen for confirmation by real-time RT-PCR analysis. These miRNAs are predicted to target elements of the HIF- $\alpha$  oxygen sensing pathway.

Identifying the molecular basis of susceptibility to OIR may help to identify infants at risk of developing ROP and identify new therapeutic targets for treatment.



## **PUBLICATIONS ARISING FROM THIS THESIS**

**Tea, M.**, Fogarty, R., Brereton, H.M., Michael, M.Z., Van der Hoek, M.B., Tsykin, A., Coster, D.J., and Williams, K.A., Gene expression microarray analysis of early oxygen-induced retinopathy in the rat. *J Ocul Biol Dis Infor*, 2009. **2**(4): p. 190-201.

## **PRESENTATIONS ARISING FROM THIS THESIS**

**Tea MN**, van Wijngaarden P, Michael M, Brereton HM, Coster DJ, Williams KA. Altered mRNA and miRNA expression and genetic susceptibility to experimental Retinopathy of Prematurity (Poster). Lorne Genome 2011, Lorne, February 13-15.

**Tea MN**, van Wijngaarden P, Michael M, Brereton HM, Coster DJ, Williams KA. Altered miRNA and gene expression and genetic susceptibility to experimental Retinopathy of Prematurity (Poster). RNAi and miRNA Europe 2010, Dublin, September 14-15.

**Tea MN**, van Wijngaarden P, Michael M, Brereton HM, Coster DJ, Williams KA. Altered gene expression and genetic susceptibility to experimental Retinopathy of Prematurity (Poster). Lorne Genome 2010, Lorne, February 14-16.

**Tea MN**, van Wijngaarden P, Michael M, Brereton HM, Coster DJ, Williams KA. Genetic susceptibility to experimental Retinopathy of Prematurity: The role of microRNAs (Presentation). **53<sup>rd</sup> Annual Conference of Australian Society for Biochemistry and Molecular Biology (ComBio) 2009**, Christchurch, December 6-10.

**Tea MN**, van Wijngaarden P, Michael M, Brereton HM, Coster DJ, Williams KA. Genetic susceptibility to experimental Retinopathy of Prematurity: The role of microRNAs (Presentation). ASMR SA Division: Annual Scientific Meeting 2009, Adelaide, June 2.

**DECLARATION**

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Signed: \_\_\_\_\_ Date: \_\_\_\_\_

Melinda Tea

## **ACKNOWLEDGEMENTS**

I am greatly indebted to many people for their knowledge, expertise and assistance over the course of my PhD. In particular I would like to thank:

Keryn Williams for the many opportunities she has given me since she gave me my first job as a graduate. As a mentor, I could not have asked for anything more. Her unwavering confidence in me has made me the researcher I am today, and for that I am especially grateful.

Helen Brereton for passing on her knowledge of molecular biology, which has been invaluable, and for always finding time for me. I also thank her for the many enjoyable conversations on food, wine and travel we have enjoyed over the years.

Michael Michael for his never ending enthusiasm for microRNAs and my new found appreciation for the world of non-coding RNAs.

Peter van Wijngaarden whose previous findings laid the foundation for the work presented in this thesis.

Rhys Fogarty for his assistance with the Affymetrix microarray analyses.

Kirsty Kirk for her great source of knowledge and excellent technical skills, as without her, my retinal flat-mounts would have left a lot to be desired. I'm lucky to have known at a professional level as well as a personal level. No one in the lab knew me quite as well as she did.

Lauren Mortimer for her assistance in the preparation of RNA and cDNA and for keeping me company in the PCR clean room. Her constant support

and encouragement throughout the writing process, as well as the endless cups of tea and baked goods, made it all that much easier.

Gemma Lowe and Fran Angerstein for their assistance with animal handling.

Miriam Keane for her assistance with statistical analyses.

The administration staff within the Department of Ophthalmology for their kind words of encouragement over the last few months, in particular Deb Sullivan, Lyn Harding, Lynda Saunders, Anne Cazneaux and Marie Lowe.

All lab staff and students, past and present, in the Department of Ophthalmology including Alison Clarke, Alex Colella, Madi Helm, Margaret Philpott, Sonja Klebe, Paul Badenoch, Yazad Irani, David Dimasi, Kate Laurie, Alpana Dave, Sarah Martin, Abraham Kuot, Kathleen Dowell, Mona Awadalla, Shiwani Sharma, Kathryn Burdon and Claire Jessup. Their expertise, feedback and friendship have been invaluable.

Stuart Lisk, Theresa Fischer, Jasmine Scottney-Turbill and *Minetta* Hedger-Smith at the animal house facility for their assistance in animal breeding.

Anne-Louise Smith and staff of the Department of Biomedical Engineering for constructing the oxygen chamber and for providing ongoing support and maintenance.

Mark van der Hoek, Rosalie Kenyon and Anna Tsykin at the Adelaide Microarray Consortium for their assistance in experimental design, performing the arrays and statistical analyses.

Oliver van Wageningen for sequencing PCR products.

A special mention to Sarah and Richard Appleby, who have been through it all before. Their friendship, support and most of all, understanding, made it much easier to keep going. They will be missed very much when they embark on their overseas adventure.

To my closest friends, Simone and Alex, who have seen less and less of me over the course of my PhD, but still consider me a friend.

To Ché, who has put up with what I affectionately called the “PhD crazies” and never complained once. It mustn’t have been easy and words can’t begin to explain how lucky I’ve been to have his love and support throughout it all.

Finally, heartfelt thanks to my family who have supported me in every way possible throughout the course of my PhD. I could not have done it without their love and encouragement, for which I am eternally grateful.

## ABBREVIATIONS

$\leq$	less than or equal to
$\geq$	more than or equal to
$\sim$	approximately
$^{\circ}\text{C}$	degrees Celsius
$\mu\text{g}$	microgram ( $10^{-6}$ g)
$\mu\text{l}$	microlitre ( $10^{-6}$ l)
$\mu\text{M}$	micromolar ( $10^{-6}$ M)
$\mu\text{m}$	micrometer ( $10^{-6}$ m)
AAKT	<i>apoptosis-associated tyrosine kinase</i>
AE	<i>amplification efficiency</i>
Aga	<i>Anopheles gambiae</i>
AGO1-4	argonaute 1/2/3/4 protein
ANG1	angiopoietin 1
ANG2	angiopoietin 2
ANOVA	analysis of variance
ARBP	acidic ribosomal phosphoprotein
ARVO	Association for Research in Vision and Ophthalmology
BEAT-ROP	Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity
bFGF	basic fibroblast growth factor
BN	Brown Norway rat strain
BNIP3	BCL2/adenovirus E1B 19 kDa-interacting protein 3
bp	base pairs
CA	California
CBP	creb-binding protein
cDNA	complementary DNA
CI	confidence interval
cm	centimetre
$\text{CO}_2$	carbon dioxide
COX 2	cyclooxygenase 2
Ct	cycle threshold
DA	Dark Agouti rat strain
DAVID	Database for Annotation, Visualisation and Integrated Discovery
ddH <sub>2</sub> O	double distilled water

DE	Delaware
DEPC	diethylpyrocarbonate
DMOG	dimethyloxalylglycine
DNA	deoxyribonucleic acid
dNTP	dinucleotide triphosphate
DOPA	dihydroxyphenylalanine
DTT	dithiothreitol
dTTP	deoxythymidine triphosphate
EC	endothelial cell
EDTA	ethylene-diamine-tetraacetic-acid
EFNA3	Ephrin-A3
EGLN1	EGL nine homolog 1/PHD2
EGLN2	EGL nine homolog 2/PHD1
EGLN3	EGL nine homolog 3/PHD3
EPO	erythropoietin
EtOH	ethanol
F <sub>(x,y)</sub>	F statistic (degrees of freedom, error)
F344	Fischer 344 rat strain
FDR	false discovery rate
FEVR	familial exudative vitreoretinopathy
FIH-1	factor-inhibiting HIF-1
FRA	F344 room air-exposed rat
FO <sub>2</sub>	F344 cyclic hyperoxia-exposed rat
g	gram
g	gravity
GEO	gene expression omnibus
GO	gene ontology
GS-IB4	<i>Griffonia simplicifolia</i> type I isolectin B4-Alexa 488™ conjugate
h	hour
HK2	hexokinase 2
HIF-α	hypoxia inducible factor-α
HIF-1	hypoxia inducible factor-1
HIF-1/2α	hypoxia inducible factor-1/2α
HPRT	hypoxanthine guanine phosphoribosyl transferase
HRE	hypoxia response element
Hsa	<i>Homo sapien</i>
HUVEC	human umbilical vein endothelial cell



HW	Hooded Wistar rat strain
ICROP	International Classification of Retinopathy of Prematurity
IGF-1	insulin-like growth factor-1
IGFBP2/3	insulin-like growth factor binding protein 2/3
IL	Illinois
Kb	kilobases
l	litre
LE	Long Evans rat strain
LNA	locked nucleic acid
log	logarithm
M	molar
m	metre
MA	Massachusetts
mg	milligram ( $10^{-3}$ g)
min	minutes
miRNA	microRNA
ml	millilitre ( $10^{-3}$ l)
mm	millimetre ( $10^{-3}$ m)
mM	millimolar ( $10^{-3}$ M)
Mmu	Mus musculus
MNE	mean normalised expression
Mo	Missouri
mRNA	messenger ribonucleic acid
MW	molecular weight
n	number/sample size
NaCl	sodium chloride
ND	not determined
NE	normalised gene expression
ng	nanogram ( $10^{-9}$ g)
NJ	New Jersey
nm	nanometre ( $10^{-9}$ m)
NSW	New South Wales
O <sub>2</sub>	oxygen, cyclic hyperoxia exposure
OIR	oxygen-induced retinopathy
OR	Oregon
PBS	phosphate buffered saline
p300	creb-binding protein homolog

PCA	principal components analysis
PCR	polymerase chain reaction
PDGF- $\beta$	platelet derived growth factor- $\beta$
PEDF	pigment epithelium derived factor
PHD	Prolyl hydroxylase
PHD1	PHD1/EGLN2
PHD2	PHD2/EGLN1
PHD3	PHD3/EGLN3
pre-miR	primary precursor microRNA transcript
pri-miR	precursor microRNA transcript
R <sup>2</sup>	coefficient of determination of a linear <i>regression</i>
RA	room air
Ref	reference
RIN	RNA integrity number
RISC	RNA-induced silencing complex
RNA	ribonucleic acid
RNA Pol II	RNA polymerase 2
Rno	<i>Rattus norvegicus</i>
ROP	retinopathy of prematurity
RPE	retinal pigment epithelium
rpm	revolutions per minute
RT	room temperature
RT-	reverse transcriptase-free; negative control cDNA
RT-PCR	reverse transcription-polymerase chain reaction
sec	second
SA	South Australia
SCD	sickle cell disease
SCF	stem cell factor
SD	Sprague Dawley rat strain. Note that in the context of statistical analysis, standard deviation is also abbreviated to SD.
SDRA	Sprague Dawley room air-exposed rat
SDO <sub>2</sub>	Sprague Dawley cyclic hyperoxia-exposed rat
SLC16A3	Solute carrier family 16, member 3
snRNA	small nuclear RNA
snoRNA	small nucleolar RNA
SV40	Simian Vacuolating <i>Virus</i> 40
TBE	tris borate EDTA

TGF- $\beta$	transforming growth factor- $\beta$
Tie2	tyrosine kinase with Ig and epidermal growth factor homology domain receptor 2: receptor for angiopoietin-1 & -2
T <sub>m</sub>	melting temperature
TRBP	TAR RNA-binding protein
TX	Texas
TYR	tyrosinase
U	units
Ub	Ubiquitin
UK	United Kingdom
UNG	Uracil-DNA glycosylase enzyme
USA	United States of America
UV	ultraviolet light
V	volt
v	version; volume
v/v	unit volume per unit volume
VEGF	vascular endothelial growth factor (VEGF A unless otherwise specified)
VEGFR-2	vascular endothelial growth factor receptor-2
VHL	von Hippel-Lindau protein
VIC	Victoria
w/v	unit weight per unit volume
WA	West Australia
WF	Wistar-Furth rat strain
WI	Wisconsin
x	times / multiplication factor